Boonah and Kalbar Medical Centres 1 / 7
NIP Schedule — 2026

Funded Immunisations
for Patients 50 and Older

A summary of vaccines available at no cost under the National Immunisation Program, incorporating schedule updates effective from mid-2026.

Influenza Pneumococcal Shingles RSV COVID-19
Boonah and Kalbar Medical Centres 2 / 7
Annual Vaccine

Influenza (Flu)

One dose recommended each year, ideally April–May before winter

Adults aged 65 years and over High-dose or adjuvanted formulation (Fluad Quad) available on NIP Funded
Aboriginal and Torres Strait Islander people — any age Funded
Adults aged 50–64 years Funded under the Queensland Immunisation Program Funded
Boonah and Kalbar Medical Centres 3 / 7
New from 1 July 2026

Pneumococcal Capvaxive® (21vPCV)

Replaces Prevenar 13® and Pneumovax 23® — simplified to a single vaccine with broader coverage

Adults aged 65 years and over Single dose; previously vaccinated adults eligible =12 months after last pneumococcal dose Funded
ATSI adults aged 25 years and over Funded
Adults aged 18+ with specified medical conditions Newly expanded to include COPD and chronic liver disease — see note Funded
Adults 50–64 — no risk factors, non-ATSI Not funded
Medical risk conditions (18+ yrs): Immunocompromising conditions · Asplenia or splenic dysfunction · Chronic cardiac disease · Chronic respiratory disease (incl. COPD — newly eligible 2026) · Chronic renal disease · Chronic liver disease (newly eligible 2026) · Diabetes mellitus · CSF leak · Cochlear implant. Full list: Australian Immunisation Handbook, pneumococcal chapter.
Boonah and Kalbar Medical Centres 4 / 7
2-Dose Course

Herpes Zoster (Shingles) Shingrix® (RZV)

Recombinant subunit vaccine — two doses required for full protection

Adults aged 65 years and over 2 doses, 2–6 months apart Funded
ATSI people aged 50 years and over 2 doses, 2–6 months apart Funded
Adults aged 18+ with moderate or severe immunocompromise 2 doses given 1–2 months apart (accelerated schedule) — see note for qualifying conditions Funded
Adults 50–64 — immunocompetent, non-ATSI Not funded
Immunocompromised (18+ yrs) — qualifying examples: Haematological malignancy · Solid organ or haematopoietic stem cell transplant · HIV infection · Significant immunosuppressive therapy. Not all immunocompromised patients qualify — moderate/severe categories apply. Full criteria: Australian Immunisation Handbook zoster risk-conditions table.
Boonah and Kalbar Medical Centres 5 / 7
New — Funded from 15 May 2026

RSV Arexvy® (RSVPreF3 OA)

Single dose · Protection lasts at least 2 years · Revaccination timing under review

All adults aged 75 years and over Single intramuscular dose Funded
ATSI adults aged 60 years and over Single intramuscular dose Funded
Adults aged 60–74 — non-ATSI Available privately; discuss with GP Not funded
Adults aged 50–59 — with or without risk factors Arexvy is registered for this age group with risk factors, but not NIP-funded; discuss with GP Not funded
Note on Abrysvo®: The other registered RSV vaccine (Abrysvo) is NIP-funded only for pregnant women (28–36 weeks gestation) to protect newborns — it is not part of the adult 50+ program.
Boonah and Kalbar Medical Centres 6 / 7
NIP-Funded Groups Only

COVID-19 Comirnaty® (LP.8.1)

Annual vaccination based on age and medical risk — primary course recommendations no longer apply

All adults aged 75 years and over Recommended: 2 doses per year, approximately 6 months apart Funded
Adults aged 65–74 years Recommended: 1 dose per year · a second annual dose can be considered if a medical risk condition is present Funded
Aboriginal and Torres Strait Islander adults aged 50–74 years Recommended: 1 dose per year · a second annual dose can be considered if a medical risk condition is present Funded
Adults aged 18–64 with severe immunocompromise Recommended: 1 dose per year · a second annual dose can be considered Funded
Adults aged 18–64 without severe immunocompromise With or without other medical risk conditions — a dose each year can be considered; not NIP-funded, discuss with GP Not funded
Funding: The NIP funds COVID-19 vaccine for adults 75+ (2 doses/year), adults 65–74, Aboriginal and Torres Strait Islander adults 50–74, and adults 18+ with severe immunocompromise (1 dose/year) — for people who hold, or are eligible for, a Medicare card. A second annual dose for those with medical risk conditions is a Handbook recommendation — confirm funding on the current NIP Schedule. Timing: space 2 doses a year about 6 months apart; protection lasts at least 4–6 months, so do not defer by season. COVID-19 vaccine can be co-administered with any other vaccine in people aged ≥5 years, including influenza.
Boonah and Kalbar Medical Centres 7 / 7
Quick Reference

Eligibility at a Glance

NIP-funded vaccines — patients aged 50 and older · 2026 schedule

Vaccine 50–64 (general) 50–64 (ATSI) 50+ (medical risk) 65–74 75+
Influenza (annual) ✓ QIP ✓ ✓ ✓ ✓
Pneumococcal Capvaxive® — ✓ (25+) ✓ ✓ ✓
Shingles Shingrix® — ✓ (50+) ⚠ immunocomp.
only (18+)
✓ ✓
RSV Arexvy® — ✓ (60+) — — ✓
COVID-19 — consider
(not funded)
✓ (50–74) ✓ severe
immunocomp. only
✓ 1 dose/yr ✓ 2 doses/yr
Sources: Australian Government Department of Health NIP Schedule (June 2026) · Australian Immunisation Handbook · Changes effective 15 May 2026 (RSV Arexvy) and 1 July 2026 (Capvaxive). Always verify current eligibility with the Handbook or health.gov.au.